Targeted Therapy
Brand names:
Afinitor®, Afinitor Disperz®, Zortress®
Often used for:
Renal cell carcinoma (a type of kidney cancer); Subependymal giant cell astrocytoma (a type of brain tumor); Prevention of organ rejection after kidney or liver transplant; Prevention of seizures in patients tuberous sclerosis complex
Everolimus (Afinitor®, Zortress®) is a type of medicine called a targeted therapy. This medicine is an mTOR inhibitor. It acts to block certain cell signals to help keep cells from growing. It can also help block the growth of blood vessels that supply oxygen to tumors. Everolimus may also be used to prevent rejection of organ transplants.
Female patients of childbearing age will be given a pregnancy test before starting this medicine. Patients will have regular blood draws to check blood counts and monitor liver and kidney function. This drug may increase the risk of infection.
May be taken as a tablet by mouth
May be taken as a liquid by mouth
Symptoms of an allergic reaction include: rash, hives, itching, chills, fever, headache, muscle ache, shortness of breath, coughing, tightness in the throat, swelling of the face or neck.
Not all patients who take everolimus will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Some patients may experience long-term or late effects of treatment that may continue or develop months or years after treatment ends. Possible late effects due to everolimus include:
Be sure to discuss these and other recommendations with your doctor or pharmacist.